DDInter112 DDInter596
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Aprepitant {u} (Compound) palliates {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) causes {v} (Side Effect) Mucous membrane disorder
Mucous membrane disorder {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) palliates {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Idarubicin
Idarubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) causes {v} (Side Effect) Mucous membrane disorder
Mucous membrane disorder {u} (Side Effect) is caused by {v} (Compound) Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) resembles {v} (Compound) Fosaprepitant
Fosaprepitant {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Stevens-Johnson syndrome {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) prostate cancer
prostate cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) interacts with {v} (Gene) POR
POR {u} (Gene) is bound by {v} (Compound) Doxorubicin
Aprepitant {u} (Compound) palliates {v} (Disease) breast cancer
breast cancer {u} (Disease) resembles {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Aprepitant (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Doxorubicin (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Aprepitant (Compound) causes Mucous membrane disorder (Side Effect) and Mucous membrane disorder (Side Effect) is caused by Doxorubicin (Compound)
Aprepitant (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Idarubicin (Compound) and Idarubicin (Compound) resembles Doxorubicin (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Aprepitant (Compound) causes Mucous membrane disorder (Side Effect) and Mucous membrane disorder (Side Effect) is caused by Epirubicin (Compound) and Epirubicin (Compound) resembles Doxorubicin (Compound)
Aprepitant (Compound) resembles Fosaprepitant (Compound) and Fosaprepitant (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Doxorubicin (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with prostate cancer (Disease) and prostate cancer (Disease) is treated by Doxorubicin (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) interacts with POR (Gene) and POR (Gene) is bound by Doxorubicin (Compound)
Aprepitant (Compound) palliates breast cancer (Disease) and breast cancer (Disease) resembles ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Doxorubicin (Compound)